SOAT1 and rheumatoid arthritis: For example, JAK inhibitors such as Tofacitinib and Ruxolitinib have been approved for the treatment of rheumatoid arthritis, psoriasis, and certain types of blood cancers.319 These inhibitors offer targeted therapy options that aim to restore normal immune function or suppress aberrant cell growth driven by dysregulated JAK/STAT signaling.